Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL-6 receptor inhibitors for severe COVID-19 pneumonia
2020-001275-32Phase 2Terminated
- Sponsor
- Parker Institute for Cancer Immunotherapy
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in coronavirus disease 2019 (COVID-19) and coronavirus pneumonia comparing Tocilizumab plus standard of care, Sarilumab plus standard of care and Standard of care without adjuvant IL-6 inhibition (3 arms). Primary endpoint: Time to independence from supplementary oxygen therapy. Started Mar 2020; status: terminated.
02
Drugs
tocilizumabsarilumab
03
Conditions
coronavirus disease 2019 (COVID-19)coronavirus pneumonia
Beyond the preview
Go deeper on 2020-001275-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001275-32.